187 related articles for article (PubMed ID: 34436603)
1. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
Mendes RE; Doyle TB; Streit JM; Arhin FF; Sader HS; Castanheira M
J Antimicrob Chemother; 2021 Oct; 76(11):2833-2838. PubMed ID: 34436603
[TBL] [Abstract][Full Text] [Related]
2. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
3. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
Livermore DM; Mushtaq S; Vickers A; Woodford N
Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of ceftazidime/avibactam resistance in drug-naïve bacteraemic Enterobacterales strains without metallo-beta-lactamase production: Associated with ceftazidime impedance.
Xiong L; Wang Y; Wang X; Zhou Y; Chi X; Chen T; Lu P; Chen Y; Ji J; Xiao Y
Int J Antimicrob Agents; 2023 Aug; 62(2):106877. PubMed ID: 37271474
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017.
Estabrook M; Kazmierczak KM; Wise M; Arhin FF; Stone GG; Sahm DF
J Glob Antimicrob Resist; 2021 Mar; 24():316-320. PubMed ID: 33524556
[TBL] [Abstract][Full Text] [Related]
6. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
Gales AC; Stone G; Sahm DF; Wise MG; Utt E
J Antimicrob Chemother; 2023 Jul; 78(7):1606-1615. PubMed ID: 37161662
[TBL] [Abstract][Full Text] [Related]
7. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE
J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae.
Niu S; Wei J; Zou C; Chavda KD; Lv J; Zhang H; Du H; Tang YW; Pitout JDD; Bonomo RA; Kreiswirth BN; Chen L
J Antimicrob Chemother; 2020 Mar; 75(3):559-565. PubMed ID: 31722380
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
Alm RA; Johnstone MR; Lahiri SD
J Antimicrob Chemother; 2015 May; 70(5):1420-8. PubMed ID: 25634992
[TBL] [Abstract][Full Text] [Related]
11.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
12. Aztreonam-avibactam may not replace ceftazidime/avibactam: the case of KPC-21 carbapenemase and penicillin-binding protein 3 with four extra amino acids.
Ma K; Feng Y; Zong Z
Int J Antimicrob Agents; 2022 Sep; 60(3):106642. PubMed ID: 35872296
[TBL] [Abstract][Full Text] [Related]
13. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases.
Feng K; Jia N; Zhu P; Sy S; Liu Y; Dong D; Zhu S; Zhang J; Liu Y; Martins FS; Gong H; Lv Z; Yu M; Sy SKB; Zhu Y
J Antimicrob Chemother; 2021 Oct; 76(11):2875-2883. PubMed ID: 34383928
[TBL] [Abstract][Full Text] [Related]
14. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
15. Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.
Mushtaq S; Vickers A; Woodford N; Livermore DM
Int J Antimicrob Agents; 2024 Mar; 63(3):107081. PubMed ID: 38176458
[TBL] [Abstract][Full Text] [Related]
16. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.
Xu C; Wei X; Jin Y; Bai F; Cheng Z; Chen S; Pan X; Wu W
Microbiol Spectr; 2022 Oct; 10(5):e0139022. PubMed ID: 35972286
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
18. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
Shen Z; Ding B; Ye M; Wang P; Bi Y; Wu S; Xu X; Guo Q; Wang M
J Antimicrob Chemother; 2017 Jul; 72(7):1930-1936. PubMed ID: 28333323
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
20. Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales.
Mushtaq S; Vickers A; Ellaby N; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 Dec; 77(1):98-111. PubMed ID: 34568905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
